Promising Data Presented at AACR Further Support New Lung Cancer Treatment Combination as Well as Ongoing Studies of Peregrine's Bavituximab

Peregrine Pharmaceuticals Announces Receipt of Notice From NASDAQ

Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2012 Financial Results and Recent Developments

Peregrine Reports Data From Phase II Front-Line Lung Cancer Trial

Peregrine to Report Third Quarter Fiscal Year 2012 Financial Results After Market on March 9, 2012

Peregrine Announces Seven Abstracts Accepted for Presentation at AACR 2012 Annual Meeting

Peregrine Announces Participation at Upcoming Investor Conferences in March

Avid Bioservices to Present at IBC's Antibody Development and Production Conference

Peregrine to Present at BIO CEO and Investor Conference on Tuesday, February 14, 2012 at 8:30 AM EST

Peregrine Provides Update on HCV Clinical Program